SCHEMBL18839705

SCHEMBL18839705

CO[C@H](c1c(C(=O)O)cnc2cc(F)nn12)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MALT1 Q9UDY8 13/20 0.41
▸ NPC1 O15118 4/20 0.36
▸ RAB9A P51151 4/20 0.36
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ HPGD P15428 3/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ HSD17B10 Q99714 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CYP1A2 P05177 1/20 0.34
▸ BIRC3 Q13489 2/20 0.34
▸ ALDH1A1 P00352 4/20 0.33
▸ GAA P10253 1/20 0.32
▸ PKM P14618 1/20 0.32
▸ NFKB1 P19838 1/20 0.30
▸ NFKB2 Q00653 1/20 0.30
▸ RELA Q04206 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18839707 1.00 MALT1 (0.41) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL17293002 0.88 MALT1 (0.41) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL17293001 0.88 MALT1 (0.41) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL22408846 0.86 CYP1A2 (0.49) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL18862726 0.86 CYP1A2 (0.49) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL17293051 0.85 MALT1 (0.52) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL18787657 0.85 MALT1 (0.52) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL17293052 0.85 MALT1 (0.52) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL18787694 0.77 MALT1 (0.45) MALT1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL20913179 0.77 MALT1 (0.45) MALT1NPC1RAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200289514-A1 Novel Pyrazolo Pyrimidine Derivatives NOVARTIS PHARMA AG (CH) 2020-09-17 — — US disclosed
US-20200289514-A1 Novel Pyrazolo Pyrimidine Derivatives NOVARTIS PHARMA AG (CH) 2020-09-17 — — US disclosed
EP-3374361-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES Novartis AG (CH) 2018-09-19 — — EP disclosed
WO-2017081641-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2017-05-18 — — WO disclosed
WO-2017081641-A1 NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES NOVARTIS AG (CH) 2017-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200289514-A1 Novel Pyrazolo Pyrimidine Derivatives MMEL1, PPME1, CTSC MALT1 4/4885NPC1 2479/4885RAB9A 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback